Making a Difference In Patient’s Lives
Welcome
We are a radiopharmaceutical company dedicated to advancing healthcare through innovative diagnostic and therapeutic solutions. Our focus is on developing cutting-edge technologies for oncology, rare pediatric diseases, infectious diseases, and biomedical countermeasures.
About Us
Advanced Innovative Partners is a global, clinical-stage biotechnology company developing innovative diagnostic and therapeutic (theranostic) products that leverage the power of targeted radiation. We have a robust pipeline spanning breast, lung, brain, and solid tumor cancers, as well as rare diseases, all supported by a reliable, secure global supply chain and a network of collaborative partners.
Our diverse portfolio of products in various stages of development reflects our commitment to transforming the standard of care and improving outcomes for patients facing some of the most challenging medical conditions. By seamlessly integrating advanced diagnostics and precisely targeted therapies, we strive to enable earlier detection, more effective treatment, and better quality of life for those impacted by complex, hard-to-treat diseases.
Our mission is to equip clinicians with the tools they need to gain deeper insights into complex diseases and deliver more effective treatments, ultimately improving outcomes for patients. By seamlessly integrating our novel diagnostics and therapies, we strive to transform the standard of care and make a meaningful impact on the lives of those affected by some of the most challenging medical conditions.
Mission
Our mission is to develop innovative diagnostic and therapeutic products that significantly improve patient outcomes and quality of life. We are committed to researching, developing, and providing specialized radiopharmaceuticals, precision medicines, and biomedical solutions for hard-to-treat diseases. By leveraging advanced technologies and a patient-centric approach, we aim to transform the standard of care and make a profound difference in the lives of those affected by complex, rare, and challenging medical conditions
Vision
Our vision is to transform patient care by being at the forefront of precision medicine and targeted therapies. We strive to develop breakthrough solutions that enable the early detection and effective treatment of challenging diseases, with the goal of extending and enhancing the lives of those affected. By leveraging cutting-edge technology, deep scientific expertise, and a relentless focus on innovation, we aim to redefine the standard of care and provide patients with the best possible outcomes.
Our Purpose
We are dedicated to developing targeted therapies and advancing disease detection and treatment through an integrated approach spanning proprietary technology platforms, strategic partnerships, and a patient-centric focus. Our purpose is to profoundly improve patient journeys by enabling earlier, more accurate diagnoses and providing more powerful yet gentler treatments, giving patients the best chance for better outcomes. Our goal is to make a meaningful difference for those impacted by complex, aggressive, rare, and infectious diseases around the world.
PET Scans - Nuclear Medicine
Radiopharmaceuticals, consisting of radioconjugated tracers, have been vital tools in oncology and epidemiology for decades. PET (Positron Emission Tomography) scans utilize these radiotracers as powerful diagnostic tools, visually highlighting abnormal functional processes in the body to identify cancers, infections, and other conditions.
PET technology enables:
- Precise disease detection
- Visualization of metabolic abnormalities
- Earlier diagnosis compared to some other imaging methods
While primarily used for diagnostics, radiopharmaceuticals also show increasing promise for targeted therapeutic applications, potentially offering more precise treatment options for various diseases.
OUR TARGETS
AIP is developing a diverse portfolio of technologies aimed at addressing unmet medical needs including oncology, rare pediatric diseases, infectious diseases, and biomedical countermeasures. Our focus is on developing innovative therapeutic and diagnostic solutions that are closely integrated and personalized to patients.
Oncology
Our robust oncology portfolio comprises multiple theragnostic agents to enable precise diagnosis and treatment across various cancer types.
Infectious Disease
Our infectious disease pipeline features diagnostic and therapeutic radiopharmaceuticals to facilitate rapid, precise diagnosis of various
Rare Pediatric Diseases
Our rare disease portfolio features diagnostic agents intended to address a variety of rare and disabling childhood conditions.
Biomedical Countermeasures
Our biomedical countermeasures pipeline comprises specialized drugs to bolster medical countermeasures against biological, radiological
CORE ETHICS
Founder and Chairman
Dr. Stanley Satz is a pre-eminent radiation physicist with over 40 years of experience, specializing in radiopharmaceuticals for targeted cancer therapy. His leadership spans from pharmaceuticals, defense and academia. Dr. Satz was awarded the first patent on accelerator production of Actinium-225 and a pioneer in the application of alpha emitting radioisotopes for medical use
Expertise and experience in nuclear physics at Advanced Innovative Partners (AIP) as Chief Scientific Officer
Founded Bio-Nucleonics, Inc., securing FDA approval for Strontium Chloride (Sr-89) to treat cancer bone pain
Former Professor at the University of Miami and Chairman of the Scientific Advisory Board at Florida Atlantic University
Ph.D. in Nuclear Physics
Our Team
Stanley Satz, Ph.D
Founder and Chairman
Roseanne Satz
Chief Executive Officer
Colm King
Chief Financial Officer
Hamid Zolata, M.D., Ph.D.
Chief Medical Officer
Sylvia Mergul, Ph.D
VP Clinical R&D
Brian Burnett. M.Sc.
Director, Drug Development
Greg Waterburry
VP Strategic Development
Our Advisors
Anne Harrington
Advisor - State Department
Paul Crowe
Radiopharmaceutical Advisor
Gerardo Morales
Board Advisor
Jim Self
Business Development Advisor
Thom Tulip, PhD.
Radiopharmaceutical Advisor
